Vasculitis associated with tumor necrosis factor-α inhibitors
about
Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overviewReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseCardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.Digital vasculitis in a patient with rheumatoid arthritis responded well to adalimumab.Large Vessel Vasculitis Occurring in Rheumatoid Arthritis Patient under Anti-TNF Therapy.Rheumatoid vasculitis: going, going, but not yet gone.Severe Henoch-Schönlein purpura with infliximab for ulcerative colitisSystemic adalimumab induces peripheral corneal infiltrates: a case report.An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's diseaseNon-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors.Impaired function of endothelial progenitor cells in children with primary systemic vasculitis.Nodular Vasculitis That Developed during Etanercept (Enbrel) Treatment in a Patient with Psoriasis.The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.Paradoxes in dermatology.Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literatureRemission of severe aphthous stomatitis of celiac disease with etanercept.Vasculitis associated with rheumatoid arthritis: a case-control studyA practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis.Neutrophilic dermatoses: an update.Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease.Prevention of Stroke in Rheumatoid Arthritis.Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects.Biological Therapy-Induced Systemic Vasculitis.Cutaneous side-effects of biologics in immune-mediated disorders: A histopathological perspective.Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitisGenome Engineering for Personalized Arthritis Therapeutics.Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.Etanercept treatment-related c-ANCA-associated large vessel vasculitis.Anti–NMDAR encephalitis in a patient with Crohn disease receiving adalimumab.
P2860
Q26738918-556DCAF2-566A-45E5-921E-6AF87571C469Q26822029-EBE87382-2B4B-4499-ADF2-ED66D172ED2DQ30240180-4A6D98ED-92FA-4922-B446-45FC7879ACD9Q30826279-B31BC271-6199-4ADE-92B1-1091E9EF8DB8Q34009656-A35601C2-E023-4A12-94F7-1A7845587B2FQ34722599-A2FD5768-CF07-4C34-92E5-2E3FFFEBAC6AQ35584031-54221EB8-FBFF-4241-82F9-C3AD9F58CE03Q35625482-AEEFCD86-AE39-4A79-9A1D-88CE69BDEB6BQ35686285-948F0CE2-78F3-4D36-ACB2-40714D662371Q35846531-73076D38-D30E-441E-BAA6-23866B2F78EFQ36160532-D46BC165-FE3F-4D90-B7D0-677039875315Q36172162-58DC3A0A-7957-4BE4-BF51-EDA51D407629Q36214266-3B885D70-3D19-465A-AB50-9F86AEFB4226Q36338717-7388934D-01E9-4301-822D-7E3EA385788BQ36904729-F7F04EBB-29BA-40AB-83DA-3755872C02ECQ37170458-178394A2-8F94-447F-8EA2-9FA22877C309Q37425215-0231935C-7E39-4AC6-B8A4-F21C4771913CQ37722841-331B9C1B-633C-48A3-8D35-C59A1A65B06CQ38206390-E30575DA-4F3B-4F1D-8D7E-C386710DEA34Q38242975-2907258B-C7DB-4697-90BC-5484B724D6E2Q38265958-D6867A27-3562-4548-AFFA-005EF648BC16Q38315640-2FBF2EAB-0045-4B6D-B9ED-E8F5136DDC03Q38612651-B232BB99-25B1-43F9-9844-D37E02AA440DQ38616743-781AEDBC-2C7D-496E-9DA9-6CB3E341DCC3Q38831383-124F68F6-FE38-4E27-9B65-27AEEEBE76D6Q39159787-88923B12-6C7B-4EB5-B5F3-73C2D5E102D4Q41064114-92126D42-2882-4008-87FA-6D9BCA25D6C7Q47697061-1063979F-D186-452B-BAF6-28AD04FEF9C1Q52541392-CF7B701C-257B-4740-A332-B005FA189962Q52987447-9906014C-4882-4787-95A0-102FE42BF990Q55518070-3CFED22E-DE94-4CAB-98E3-74331A913C88
P2860
Vasculitis associated with tumor necrosis factor-α inhibitors
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Vasculitis associated with tumor necrosis factor-α inhibitors
@ast
Vasculitis associated with tumor necrosis factor-α inhibitors
@en
type
label
Vasculitis associated with tumor necrosis factor-α inhibitors
@ast
Vasculitis associated with tumor necrosis factor-α inhibitors
@en
prefLabel
Vasculitis associated with tumor necrosis factor-α inhibitors
@ast
Vasculitis associated with tumor necrosis factor-α inhibitors
@en
P2093
P2860
P1476
Vasculitis associated with tumor necrosis factor-α inhibitors
@en
P2093
Ashima Makol
David A Wetter
Kenneth J Warrington
Olayemi Sokumbi
P2860
P304
P356
10.1016/J.MAYOCP.2012.04.011
P407
P577
2012-07-13T00:00:00Z